Drug Approval | March 04, 2023
Caplin Steriles gets USFDA approval for Rocuronium Bromide Injection
Rocuronium Bromide Injection is a neuromuscular blocking agent
Rocuronium Bromide Injection is a neuromuscular blocking agent
This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency
At commercial scale, Bluestem's patent pending technologies will reduce carbon emission by an estimated 75% or more and be cost-competitive with petroleum based chemicals
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
The partnership is announced at Aero India 2023, Bangalore
Label expansion for CIBINQO provides new systemic oral option for adolescents (12 to <18 years) with moderate-to-severe atopic dermatitis
This clearance allows the company to initiate a clinical trial for patients with an ileal pouch-anal anastomosis
The supplemental New Drug Application is based on results from the landmark EMPA-KIDNEY phase III trial
Swiftmelt 1515-I meets performance requirements and secures skin attachment
Advanz Pharma will leverage its specialty, hospital, and rare disease expertise and infrastructure to commercialize AT-007 in Europe for both Galactosemia and SORD Deficiency
Subscribe To Our Newsletter & Stay Updated
